Hwang TJ, Vokinger KN - Lancet Oncology
- Commentary & Opinion
- Price, Value, and Access
Summary:
CMS should adopt validated value frameworks like the ESMO-MCBS in Medicare drug price negotiation to target the deepest discounts at low-benefit drugs, align international reference pricing baskets with comparably large markets to avoid delayed access abroad, and pass savings from these programs on to patients through reduced cost-sharing.
VIEW SOURCE
Recent Work from PORTAL
Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
- Research Publications
- Price, Value, and Access
Coverage and Costs for Medications After Medicare Price Negotiation
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
- Research Publications
- Price, Value, and Access
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open
- Research Publications
- Price, Value, and Access
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.